OpiCalc

Favorites Specialties Drugs Guidelines Most Used

All Specialties

Favorites Specialties Drugs Guidelines Most Used

Faves Specs Drugs Guides Top

APGAR Score Assisted Delivery (FIGO)BPP (Manning Score)Bishop Score CARPREG II Cardiac Risk Cervical Cancer Staging Contraceptive Pearl Index Doppler Matrix (UA/MCA)EFW (Hadlock)Endometrial Staging Endometrial Thickness FGR Criteria (Consensus)FSFI (Sexual Function)Ferriman-Gallwey Score Fetal Anemia (MCA PSV)GDM Diagnostic Criteria GPA History Indicator Gail Model Breast Risk Gestational Dating (LMP)HIV PMTCT Protocol IOTA Simple Rules IVF Due Date & AMH Iron Deficit (Ganzoni)Labour Progress (WHO)Maternal Sepsis (qSOFA)O-RADS Classification Ovarian Cancer Staging PAS Hemorrhage Risk PPH Protocol (FIGO)Preeclampsia (ACOG)Rho(D) Dose (K-B)Rotterdam PCOS Criteria Syphilis Management TORCH Framework VBAC Success Probability Vulvar Cancer Staging Weight Gain (IOM)mWHO Cardiac Risk

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required

Ready for the Bedside

Resources

About Us Editorial Policy Medical Disclaimer Privacy Policy Terms of Use Cookie Policy

Support

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

In Recent Clinical News

Scanning Medical Journals

No new significant updates or guidelines matching this topic were found today. We will check again soon.

Endometrial Staging

Endometrial Staging (2023)

Molecular & Pathology Integrated

I

Confined to Corpus

IA (≤50% Myometrium) | IB (>50% Myometrium) | IC (Integrated Molecular Stage)

II

Cervical Stroma Involved

Does NOT extend beyond uterus

III

Local / Regional Spread

IIIA (Serosa/Adnexa) | IIIB (Vagina/Parametrium) | IIIC (Lymph Nodes)

IV

Bladder / Rectum / Distant

IVA (Bowel/Bladder Mucosa) | IVB (Distant Metastasis)

Molecular update: Stage I includes POLE mutations (favorable) and p53 mutations (unfavorable).

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Primary Clinical Uses

Surgical and pathological staging of endometrial carcinoma and carcinosarcoma

Directing postoperative adjuvant treatment (radiation vs chemotherapy)

The 2023 Molecular Revolution

The 2023 update was the most radical change in history. It officially incorporated molecular classification (POLEmut, MMRd, NSMP, p53abn) into the staging system. A p53-abnormal tumor is now heavily upstaged regardless of myometrial invasion, whereas a POLE-mutated tumor may be downstaged due to exceptional prognosis.

Last Comprehensive Review: 2026